JP2022516170A5 - - Google Patents
Info
- Publication number
- JP2022516170A5 JP2022516170A5 JP2021538752A JP2021538752A JP2022516170A5 JP 2022516170 A5 JP2022516170 A5 JP 2022516170A5 JP 2021538752 A JP2021538752 A JP 2021538752A JP 2021538752 A JP2021538752 A JP 2021538752A JP 2022516170 A5 JP2022516170 A5 JP 2022516170A5
- Authority
- JP
- Japan
- Prior art keywords
- labeled
- composition
- cells
- parp inhibitor
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788206P | 2019-01-04 | 2019-01-04 | |
| US62/788,206 | 2019-01-04 | ||
| PCT/US2020/012016 WO2020142583A1 (en) | 2019-01-04 | 2020-01-02 | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022516170A JP2022516170A (ja) | 2022-02-24 |
| JP2022516170A5 true JP2022516170A5 (https=) | 2023-01-19 |
Family
ID=71406723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538752A Pending JP2022516170A (ja) | 2019-01-04 | 2020-01-02 | Ｐａｒｐインヒビターおよび抗体放射性物質結合体の組み合わせを使用してがんを処置するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20220072167A1 (https=) |
| EP (1) | EP3906061A4 (https=) |
| JP (1) | JP2022516170A (https=) |
| CA (1) | CA3125197A1 (https=) |
| WO (1) | WO2020142583A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220275090A1 (en) * | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| WO2022217060A1 (en) * | 2021-04-09 | 2022-10-13 | Cardiff Oncology, Inc. | Cancer treatment using parp inhibitors and plk1 inhibitors |
| EP4209217A1 (en) * | 2022-01-11 | 2023-07-12 | Fundación Profesor Novoa Santos | Method for the treatment of brca1/2 mutated cancer |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2024263637A1 (en) * | 2023-06-20 | 2024-12-26 | The Regents Of The University Of California | Combination therapy with peptide receptor radionuclide and dna repair inhibitor |
| CN116726187B (zh) * | 2023-07-26 | 2025-09-30 | 珠海市人民医院 | 一种小分子配体-鲁卡帕尼偶联物及其制备方法 |
| CN117180277A (zh) * | 2023-08-04 | 2023-12-08 | 中国辐射防护研究院 | 一种核素标记的靶向探针及其制备方法和应用 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN121793988A (zh) * | 2023-09-13 | 2026-04-03 | 东丽株式会社 | 癌的治疗、预防和/或诊断用药物组合物 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| WO2015184145A1 (en) * | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| JP6738909B2 (ja) * | 2016-05-27 | 2020-08-12 | アクティニウム ファーマシューティカルズ インコーポレイテッド | 血液悪性疾患を処置するための低用量抗体に基づく方法 |
| SG11201811564QA (en) * | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| JP6978251B2 (ja) * | 2017-03-03 | 2021-12-08 | アスラン ファーマシューティカルズ ピーティーイー リミテッド | がん治療 |
| JP2020517704A (ja) * | 2017-04-28 | 2020-06-18 | アクティニウム ファーマシューティカルズ インコーポレイテッド | α線放射免疫療法薬とともにＢＣＬ−２インヒビターを使用してがんを処置するための方法 |
| WO2020064693A1 (en) * | 2018-09-25 | 2020-04-02 | Advanced Accelerator Applications (Italy) Srl | Combination therapy |
| US20220088231A1 (en) * | 2018-12-03 | 2022-03-24 | Fusion Pharmaceuticals Inc. | Radioimmunoconjugates and dna damage and repair inhibitor combination therapy |
-
2020
- 2020-01-02 WO PCT/US2020/012016 patent/WO2020142583A1/en not_active Ceased
- 2020-01-02 JP JP2021538752A patent/JP2022516170A/ja active Pending
- 2020-01-02 US US17/419,381 patent/US20220072167A1/en not_active Abandoned
- 2020-01-02 CA CA3125197A patent/CA3125197A1/en active Pending
- 2020-01-02 EP EP20736050.4A patent/EP3906061A4/en active Pending
-
2024
- 2024-09-17 US US18/887,845 patent/US20250121105A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022516170A5 (https=) | ||
| JP2021120406A5 (ja) | 癌を治療するための組み合わせ物 | |
| Yim et al. | Current management of hepatocellular carcinoma: an Eastern perspective | |
| JP2022017295A5 (https=) | ||
| Kudo | Combination cancer immunotherapy in hepatocellular carcinoma | |
| JP2022511471A5 (https=) | ||
| JP2022017296A5 (https=) | ||
| Chen et al. | Role of modern radiotherapy in managing patients with hepatocellular carcinoma | |
| JP2021063120A5 (https=) | ||
| Attarbaschi et al. | Outcome of children with primary resistant or relapsed non‐Hodgkin lymphoma and mature B‐cell leukemia after intensive first‐line treatment: a population‐based analysis of the Austrian Cooperative Study Group | |
| Yamazaki et al. | Effects of radiation on tumor vasculature | |
| JP2019506392A5 (https=) | ||
| JP2020512977A5 (https=) | ||
| RU2020111019A (ru) | Полиморфная форма tg02 | |
| JP2020531463A5 (https=) | ||
| Yang et al. | Radiofrequency deep hyperthermia combined with chemotherapy in the treatment of advanced non-small cell lung cancer | |
| JP2024016209A5 (https=) | ||
| Hsieh et al. | Enhanced antitumour response of gold nanostar-mediated photothermal therapy in combination with immunotherapy in a mouse model of colon carcinoma | |
| Tanaka et al. | Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study | |
| JP2021511344A5 (https=) | ||
| Pochedly | Prophylactic CNS therapy in childhood acute leukemia: Review of methods used | |
| JP2024541900A5 (https=) | ||
| KR20230003522A (ko) | 간암에 대한 miv-818/렌바티닙 병용 요법 | |
| Koosha et al. | The effect of iodine-131 beta-particles in combination with A-966492 and Topotecan on radio-sensitization of glioblastoma: An in-vitro study | |
| Huang et al. | Metronomic S-1 chemotherapy plus transcatheter arterial chemoembolization (TACE): a promising treatment of hepatocellular carcinoma refractory to TACE |